# PRISM-1 (NCT06608927)

> Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06608927
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Arcus Biosciences, Inc.
- Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions: Quemliclustat; Placebo; Nab-paclitaxel; Gemcitabine
- Enrollment: 610
- Primary outcome: Overall Survival (OS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 2
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=prism-1-nct06608927